Mersana Therapeutics (MRSN) Misses Q2 EPS by $4.71

Mersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($4.87), $4.71 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.06 million versus the consensus estimate of $6.25 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• MIND Technology (MIND) Misses Q1 EPS by 5c
• Battery X Metals adds auto industry advisor to board